The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
Police have begun a raid on a restaurant where gunmen are suspected to be holding hostages.
Right-wing think tank warns leaving the UK in order to remain in the EU would turn Scotland into 'Greece without the sun'.
A poll of Britain's largest trade union, seen by ITV News, indicates more than half of those surveyed think the Labour leader should quit.